
News|Articles|October 1, 2012
Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis
Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement



















































